Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Luis E. Raez, MD, FACP, FCCP, about key similarities and differences between liquid and tissue biopsy and the potential benefits of liquid biopsy for determining frontline therapies for patients with metastatic non–small cell lung cancer (NSCLC).
Dr Raez is the chief scientific officer, medical director, and leader of the Thoracic Oncology Program at Memorial Cancer Institute, part of Memorial Healthcare System, in Pembroke Pines, Florida. He is also a clinical professor of medicine at Florida International University in Miami, a research professor at Florida Atlantic University in Boca Raton, and a visiting professor of medicine at Cayetano Heredia University in Lima, Peru.
In a retrospective analysis published in Clinical Lung Cancer in November 2022 of 170 patients with newly diagnosed NSCLC who received both liquid and tissue biopsy, Raez and colleagues demonstrated that physicians based 73.5% of their first-line NSCLC treatment decisions on liquid biopsy results and 25.9% of their treatment decisions on results from tissue biopsy. Additionally, this study found liquid biopsy next-generation sequencing (NGS) to be between 94.8% and 100% concordant with tissue biopsy NGS for identifying guideline-recommended biomarkers.
In our exclusive interview, Dr Raez discussed the findings from this study, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple NGS tests per patient.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.